Mesiotemporal Volumetry, Cortical Thickness, and Neuropsychological Deficits in the Long-term Course of Limbic Encephalitis.

Neurol Neuroimmunol Neuroinflamm

From the Department of Epileptology (A.H., T. Bauer, J.-A.W., T. Baumgartner, R.v.W., A.R., L.E., C.H., R.S., T.R.), and Department of Neuropathology (A.J.B.), Section for Translational Epilepsy Research, University Hospital Bonn, Germany.

Published: July 2023

Background And Objectives: Limbic encephalitis (LE) is an autoimmune disease often associated with temporal lobe epilepsy and subacute memory deficits. It is categorized into serologic subgroups, which differ in clinical progress, therapy response, and prognosis. Using longitudinal MRI analysis, we hypothesized that mesiotemporal and cortical atrophy rates would reveal serotype-specific patterns and reflect disease severity.

Methods: In this longitudinal case-control study, all individuals with antibody-positive (glutamic acid decarboxylase 65 [GAD], leucine-rich glioma-inactivated protein 1 [LGI1], contactin-associated protein 2 [CASPR2], and -methyl-d-aspartate receptor [NMDAR]) nonparaneoplastic LE according to Graus' diagnostic criteria treated between 2005 and 2019 at the University Hospital Bonn were enrolled. A longitudinal healthy cohort was included as the control group. Subcortical segmentation and cortical reconstruction of T1-weighted MRI were performed using the longitudinal framework in FreeSurfer. We applied linear mixed models to examine mesiotemporal volumes and cortical thickness longitudinally.

Results: Two hundred fifty-seven MRI scans from 59 individuals with LE (34 female, age at disease onset [mean ± SD] 42.5 ± 20.4 years; GAD: n = 30, 135 scans; LGI1: n = 15, 55 scans; CASPR2: n = 9, 37 scans; and NMDAR: n = 5, 30 scans) were included. The healthy control group consisted of 128 scans from 41 individuals (22 female, age at first scan [mean ± SD] 37.7 ± 14.6 years). The amygdalar volume at disease onset was significantly higher in individuals with LE ( 0.048 for all antibody subgroups) compared with that in healthy controls and decreased over time in all antibody subgroups, except in the GAD subgroup. We observed a significantly higher hippocampal atrophy rate in all antibody subgroups compared with that in healthy controls (all 0.002), except in the GAD subgroup. Cortical atrophy rates exceeded normal aging in individuals with impaired verbal memory, while those who were not impaired did not differ significantly from healthy controls.

Discussion: Our data depict higher mesiotemporal volumes in the early disease stage, most likely due to edematous swelling, followed by volume regression and atrophy/hippocampal sclerosis in the late disease stage. Our study reveals a continuous and pathophysiologically meaningful trajectory of mesiotemporal volumetry across all serogroups and provides evidence that LE should be considered a network disorder in which extratemporal involvement is an important determinant of disease severity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10211327PMC
http://dx.doi.org/10.1212/NXI.0000000000200125DOI Listing

Publication Analysis

Top Keywords

antibody subgroups
12
mesiotemporal volumetry
8
cortical thickness
8
limbic encephalitis
8
cortical atrophy
8
atrophy rates
8
control group
8
mesiotemporal volumes
8
scans individuals
8
individuals female
8

Similar Publications

Background: Both novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) and pertuzumab and trastuzumab (HP) combined with chemotherapy(C) regimens are the choice of treatment for HER2 positive metastatic breast cancer (MBC) after tyrosine kinase inhibitors (TKIs). Our team's previous research has shown significant therapeutic effects of novel anti-HER2 ADCs in patients with TKIs treatment failure. Unfortunately, there is currently no data available to compare novel anti-HER2 ADCs with HP combined with chemotherapy regimens.

View Article and Find Full Text PDF

Background: Qualitative patient interviews are increasingly conducted alongside clinical trials; interviews administered early in drug development can yield insight into the patient journey. Examination among patient subgroups may identify factors that influence the patient experience, including trial participation. As part of the INTERCEPT‐AD phase 1 study evaluating the safety and tolerability of the Aβ oligomer‐targeting monoclonal antibody ACU193, we conducted semi‐structured qualitative interviews among a subset of participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD) and their study partners to obtain feedback on their trial experience and the decision‐making process preceding trial enrollment; results were compared between study participant genders.

View Article and Find Full Text PDF

Background: Plasma pTau217 detects AD pathology and show longitudinal changes dependent on baseline pathology. However, previous studies have been restricted to cohorts with limited diversity. We evaluated performance of plasma pTau217 in detecting AD and predicting disease progression in a diverse cohort from the Emory Goizueta ADRC.

View Article and Find Full Text PDF

The effect of gantenerumab treatment on brain functional connectivity.

Alzheimers Dement

December 2024

Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Biomarkers, Basel, Switzerland

Background: Changes in brain functional connectivity obtained from resting state MRI (rs‐fMRI) have been found to be associated with cognitive decline and neurodegeneration in clinical trial participants with Alzheimer’s disease (AD). This study investigates whether and how this technique can be used in AD clinical trials to monitor treatment effects. Specifically, we analyzed changes in brain functional connectivity over a period of 116 weeks in participants with AD treated with gantenerumab, an investigational anti‐amyloid beta monoclonal antibody.

View Article and Find Full Text PDF

Background: Lecanemab is a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils. In two clinical studies (phase 2, NCT01767311 and phase 3 ClarityAD, NCT03887455) in early Alzheimer’s disease, lecanemab substantially reduced amyloid PET and significantly slowed clinical decline on multiple measures of cognition and function, including CDR‐SB at 18 months. Models describing the change in amyloid PET and CDR‐SB in response to lecanemab treatment were used to explore the impact of changing from the initial dosage regimen (10 mg/kg every 2 weeks [Q2W]) to a less intensive maintenance dosing regimen (10 mg/kg every 4 weeks [Q4W]) on clinical efficacy, and to explore the optimal duration of the initial dosing regimen.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!